Comparing the current results to its competitors, Mediwound Ltd reported Revenue decrease in the 4 quarter 2025 year on year by -16.14 %, despite the revenue increase by the most of its competitors of 14.67 %, recorded in the same quarter.
Mediwound Ltd 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes existing standard treatments for eschar removal in severe burns, such as surgical methods like tangential excision, dermabrasion, and hydro jet, as well as non-surgical options like topical medications. Competitors encompass medical practitioners, pharmaceutical and wound care companies, academic and medical institutions, governmental agencies, and public and private research organizations. The medical, biotechnology, and pharmaceutical sectors are highly competitive and subject to rapid technological and procedural changes. Competitors who secure regulatory or marketing authorization ahead of the company may establish strong market positions that are challenging to displace, potentially reducing demand for the company's products. Additionally, the company's commercial prospects could be adversely affected if competitors develop products, treatments, or procedures that are safer, more effective, more convenient, or less costly.
Plus Therapeutics Inc is a biotechnology company that focuses on developing precision nanoparticles for targeted therapy. They utilize their proprietary technology to create and commercialize innovative drugs for the treatment of cancer and other diseases.
United Health Products Inc. operates using a direct-to-consumer business model, providing innovative wound care products directly to customers. The company focuses on manufacturing and distributing wound dressings for different applications, offering a comprehensive range of solutions for both medical professionals and individuals seeking reliable wound management products. Overall, United Health Products Inc. aims to deliver effective, convenient, and high-quality wound care solutions directly to their target market.
Vericel Corporation's business model revolves around the development and commercialization of innovative cellular therapies for the treatment of severe diseases and conditions.
Sources:
Mediwound Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mediwound Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
